Imagion Biosystems has updated investors by lodging the latest version of its corporate presentation visuals with the Australian Securities Exchange. Content includes overviews of MagSense® Technology, the medical needs for clinical MagSense imaging, market sizes and growth rates, development milestones, and more.
View the 25 October 2017 Investor Update.
Corporate Update – IND for MagSense® HER2 Phase 2 Study Immediate Priority
Corporate Updates: $3M fundraising led by CPS Capital to be completed in early December Filing of IND for MagSense® HER2 Phase 2 Study Immediate Priority